Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Novavax phase 3 UK (2019nCoV-302), 2021 NCT04583995

Nuvaxovid (NVX-CoV2373) Novavax (n=-9) vs. placebo (n=-9)

randomized controlled trial   risk of bias NA

Studied treatment

NVX-CoV2373

Control treatment

placebo

Patients

COVID-19 prophylaxis (excluding children)

Method

double-blind

Remark

very preliminary unpublished results from a press release

Keech, 2020 NCT04368988

Nuvaxovid (NVX-CoV2373) Novavax (n=108) vs. placebo (n=23)

randomized controlled trial   risk of bias NA

Studied treatment

NVX-CoV2373
5-μg and 25-μg doses, with or without Matrix-M1 adjuvant

Control treatment

placebo

Patients

COVID-19 prophylaxis (excluding children)

Method

double blind

9 sites in Australia and 8 sites in the United States

Remark

Phase 2

Novavax PREVEND-19 phase 3 US (2019nCoV-301), 2021 NCT04611802

Nuvaxovid (NVX-CoV2373) Novavax (n=-9) vs. placebo (n=-9)

randomized controlled trial   low risk of bias

Studied treatment

NVX-CoV2373

Control treatment

placebo

Patients

COVID-19 prophylaxis (excluding children)

Method

observer-blinded

119 locations in the United States and Mexico

Efficacy endpoints were accrued from January 25 through April 30, 2021, a time when the Alpha (B.1.1.7) variant became the predominant strain in the U.S

Remark

Novavax phase 2 South Africa (2019nCoV-501), 2021 NCT04533399

Nuvaxovid (NVX-CoV2373) Novavax (n=2199) vs. placebo (n=2188)

randomized controlled trial   some concerns about risk of bias

Studied treatment

NVX-CoV2373 2 doses
two doses, administered 21 days apart, of NVX-CoV2373 nanoparticle vaccine(5 μg recombinant spike protein with 50 μg Matrix-M1 adjuvant)

Control treatment

placebo

Patients

COVID-19 prophylaxis (excluding children)

B.1.351 (501Y.V2) variant was largely predominant during trial efficacy endpoint accrual

Method

double-blind

South Africa

phase 2a/b

Remark